More than 10 Roswell Park Teams to Present New Research Findings at ASCO 2017 Annual Meeting

Conference is the largest gathering of cancer researchers and will feature three Roswell Park leaders in speaking roles
Thursday, June 1, 2017

BUFFALO, N.Y. — More than 10 teams from Roswell Park Cancer Institute have been invited to present research at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago. The research presentations cover a wide range of disciplines, treatment approaches and cancer types, including a unique form of immunotherapy for ovarian cancer, promising results on a new treatment approach for Hodgkin lymphoma in children and young adults and an effort to build a predictive tool to determine which patients are most likely to respond well to checkpoint inhibitors.

Igor Puzanov, MD, MSCI, FACP, Chief of Melanoma and Director of the Early Phase Clinical Trials Program
Marc Ernstoff, MD, Katherine Anne Gioia Chair of Medicine and Senior Vice President for Clinical Investigation

Three Roswell Park faculty leaders will have speaking roles at the meeting, which is the largest gathering of cancer researchers in the world, attracting more than 35,000 attendees:

Eunice Wang, MD, Chief of Leukemia Service
  • Igor Puzanov, MD, MSCI, FACP, Chief of Melanoma and Director of the Early Phase Clinical Trials Program, will speak on immunotherapy and novel combinations in oncology as part of a pre-Annual Meeting educational program focused on New Drugs in Oncology today from 3:45 p.m. to 5 p.m. CDT, and will also lead a poster discussion session on new research in melanoma and skin cancers on Saturday, June 3 from 4:45 p.m. 6 p.m. CDT.
  • Marc Ernstoff, MD, Katherine Anne Gioia Chair of Medicine and Senior Vice President for Clinical Investigation, will speak on the challenges in identifying patients for combination immunotherapy as part of the educational session Biomarkers for Immunotherapy: An Illusion or a Reality? on Friday, June 2 from 1 p.m. to 3:15 p.m. CDT.
  • Eunice Wang, MD, Chief of Leukemia, will lead a discussion on immunotherapy in myeloid malignancies Monday, June 5 from 11:30 a.m. to 12:45 p.m. CDT as part of the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant poster discussion session.

A summary of these research presentations and speaking roles with links to research abstracts is available at roswellpark.org/asco2017. That page and Roswell Park’s online newsroom will be updated with press releases highlighting several of these research studies.

Roswell Park President and CEO Candace S. Johnson will also take part in the annual meeting and will host a reception in Chicago on Sunday, June 4. Those interested in attending may contact Connie Brucato at Constance.Brucato@RoswellPark.org

###

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-866-559-4838) or email askrpci@roswellpark.org. Follow Roswell Park on Facebook and Twitter.

Media Contact: 

Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org